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Recent evidence suggests that the intestinemay play
a direct facilitative role in reverse cholesterol trans-
port (RCT), independent of hepatobiliary secretion.
In order to understand the nonbiliary pathway for
RCT, we created both genetic and surgical models
of biliary cholesterol insufficiency. To genetically
inhibit biliary cholesterol secretion, we generated
mice in which Niemann-Pick C1-Like 1 (NPC1L1)
was overexpressed in the liver. Compared to con-
trols, NPC1L1Liver-Tg mice exhibit a >90% decrease
in biliary cholesterol secretion, yet mass fecal sterol
loss and macrophage RCT are normal. To surgically
inhibit biliary emptying into the intestine, we have es-
tablished an acute biliary diversion model. Strikingly,
macrophage RCT persists in mice surgically lacking
the ability to secrete bile into the intestine. Collec-
tively, these studies demonstrate that mass fecal
sterol loss and macrophage RCT can proceed in
the absence of biliary sterol secretion, challenging
the obligate role of bile in RCT.
INTRODUCTION
Nearly 40 years ago, John Glomset (Glomset, 1968) presented
the seminal framework of reverse cholesterol transport (RCT),
which was described as a process by which peripheral choles-
terol is returned to the liver via high-density lipoproteins (HDLs)
for secretion into bile and excretion through the feces. In the
context of atherosclerosis, RCT is thought to involve HDL-medi-
ated efflux of cholesterol from the arterial wall, specifically from
cholesterol-laden macrophages (Wang and Rader, 2007). In
the current view of macrophage RCT, HDL-mediated delivery
of peripheral cholesterol to the liver directly promotes biliary
and fecal excretion (Lewis and Rader, 2005). Given this model,
plasma HDL levels should accurately predict both biliary sterol
secretion and fecal sterol loss. However, in mice with extremely
low HDL levels, biliary and fecal sterol loss is normal (Xie et al.,
2009; Groen et al., 2001; Jolley et al., 1998). In addition, biliary
sterol levels do not accurately predict fecal sterol loss in several
mousemodels of altered hepatic cholesterol metabolism (Brown
et al., 2008; Plosch et al., 2002; Yu et al., 2002). Collectively, this
has led us to believe that fecal cholesterol loss likely originates96 Cell Metabolism 12, 96–102, July 7, 2010 ª2010 Elsevier Inc.from two distinct excretory routes: (1) the classic hepatobiliary
route, and (2) a nonbiliary liver/ plasma lipoprotein/ small
intestine/ feces route (Brown et al., 2008). From a therapeutic
standpoint, exploiting the nonbiliary route for RCT is a much
more attractive option, since excessive augmentation of biliary
cholesterol concentrations can promote cholesterol gallstone
formation in humans (Cooper, 1991).
Preceding Glomset’s (Glomset, 1968) initial model of RCT by
40 years, the existence of a nonbiliary pathway for fecal sterol
loss was proposed first by Warren Sperry (Sperry, 1927).
Sperry’s experiments demonstrated that compared to intact
enterohepatic circulation, chronic surgical biliary diversion
paradoxically increased fecal neutral sterol loss in dogs. Nearly
a half-century later, Pertsemlidis and colleagues confirmed the
results of Sperry by demonstrating that biliary diversion resulted
in complete loss of fecal acidic sterol output, yet fecal neutral
sterol output actually increased 7-fold (Pertsemlidis et al.,
1973). Based on this observation, the authors speculated that
‘‘the increased output of fecal neutral steroids could be the result
of transfer of plasma cholesterol across the gut wall or due
to increased synthesis in the gut.’’ Similar results have been
seen under conditions of biliary diversion in rats (Bandsma
et al., 1998) and in patients with familial hypercholesterolemia
(Deckelbaum et al., 1977). Actually, as early as 1959, it was
suggested that nondietary fecal sterol loss in humans consists
of two distinct fractions: (1) the traditional fraction coming from
hepatobiliary secretion, and (2) an elusive fraction directly
secreted by the intestine (Cheng and Stanley, 1959). Unfortu-
nately, many of these early observations have been largely
ignored, and the theory that fecal sterol loss derives solely
from a biliary origin has become well accepted. However, strong
evidence for nonbiliary fecal sterol loss continues to come to
light in the age of genetically modified mice.
In a powerful example of nonbiliary fecal sterol loss in mice
(Kruit et al., 2005), it was shown that mice lacking the cannicular
phospholipid transporterMdr2, which secondarily have no biliary
cholesterol secretion, have normal fecal sterol loss. Further-
more, activation of the liver X receptor (LXR) in Mdr2/ mice
resulted in large increases in fecal sterol output, supporting the
presence of an LXR-inducible nonbiliary pathway for fecal sterol
loss (Kruit et al., 2005). Several studies from this same group
have subsequently demonstrated the existence of a nuclear
hormone receptor-inducible pathway for nonbiliary fecal sterol
loss using pioneering approaches such as in situ intestinal
perfusion and stable isotope methodologies (van der Veen
et al., 2009; Vrins et al., 2009; van der Velde et al., 2007, 2008).
However, the relative contribution of biliary and nonbiliary
Figure 1. Mice Genetically Lacking the Ability to Secrete Cholesterol
into Bile Have Normal Fecal Sterol Loss
Wild-type mice (WT) or littermates with moderate (NPC1L1-Tg-Mod) or
high-level (NPC1L1-Tg-High) overexpression of hepatic NPC1L1 were fed
diets containing 0.015% or 0.2% cholesterol (wt/wt) for 6 weeks.
(A) The concentration of cholesterol in gall bladder bile was determined by gas
liquid chromatography.
(B) Fecal neutral sterol excretion was determined by gas liquid chromatog-
raphy.
(C) Fractional cholesterol absorption was determined using the dual fecal
isotope method. Data represent the means ± SEM from four to seven mice
per group, **, significantly different than WT within each diet group, p < 0.01.
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currently known. Therefore, the purpose of these studies was
to determine the direct role of the intestine in macrophage RCT
by using novel genetic and surgical mouse models where bile
contributes minimally to fecal sterol loss.
RESULTS
NPC1L1-LiverTg Mice Serve as an Excellent Model
to Study Nonbiliary Fecal Sterol Loss
In order to characterize the role of Niemann-Pick C1-Like 1
(NPC1L1) in hepatobiliary sterol secretion and ezetimibe action,
our group previously generated two independent lines of mice
transgenically overexpressing NPC1L1 in hepatocytes (Temel
et al., 2007). As previously reported, NPC1L1 overexpression
in the liver results in a >90% reduction in gall bladder bile
cholesterol concentrations (Figure 1A), without affecting biliary
phospholipid or bile acid secretion (data not shown; Temel
et al., 2007). However, in the face of severely diminished biliary
sterol loss, fecal neutral sterol excretion in NPC1L1-LiverTg mice
is normal (Figure 1B). This disparity indicates that the nonbiliary
pathway must completely compensate for biliary sterol insuffi-
ciency in NPC1L1-LiverTg mice to maintain normal levels of fecal
sterol loss. It is important to note that fractional cholesterol
absorption (Figure 1C) and the mRNA expression of cholesterol
synthetic genes (see Figure S1A available online) in the liver and
intestine were normal in NPC1L1-LiverTg mice.
Macrophage RCT Persists in Genetically Modified Mice
with Disrupted Biliary Cholesterol Secretion
(NPC1L1-LiverTg)
In the current view of macrophage RCT, macrophage-derived
cholesterol is delivered to the liver by HDL, which shunts this
sterol cargo preferentially into the bile for subsequent fecal
excretion (Lewis and Rader, 2005; deGoma et al., 2008). We
set out to test the specific role of bile in this framework using
mice genetically lacking the ability to secrete cholesterol into
bile (NPC1L1-LiverTg). In these studies, mice were treated with
the LXR agonist T0901317, since it is known that LXR activation
promotes fecal sterol loss and macrophage RCT (Naik et al.,
2006) primarily by augmenting the nonbiliary pathway (Kruit
et al., 2005; van der Veen et al., 2009). We have previously
seen that NPC1L1-LiverTg mice are mildly hypercholesterolemic
when fed synthetic diets (Temel et al., 2007). However, when
young mice (6–8 weeks old) are maintained on standard rodent
chow, NPC1L1-LiverTg mice have similar plasma cholesterol
levels as those seen in WT littermates (Figure 2A), and the
majority of cholesterol is found in HDL (Figure 2B). When treated
with the LXR agonist T0901317, both WT and NPC1L1-LiverTg
mice exhibit mild hypercholesterolemia (164 and 166 mg/dl,
respectively), with the majority of the cholesterol elevation
seen in large HDL particles (Figure 2B), as has been previously
described (Grefhorst et al., 2002). Following [3H]-cholesterol-
labeled macrophage injection, the plasma [3H]-cholesterol
recovery was significantly higher in T0901317-treated mice
(Figure 2C). As expected, the [3H]-cholesterol distribution in
plasma (Figure 2D) tracked closely with the cholesterol mass
distribution (Figure 2B). Importantly, in WT mice, there was
LXR-inducible biliary [3H]-cholesterol secretion (Figure 2E),whereas NPC1L1-LiverTg mice had barely detectable biliary
[3H]-cholesterol levels (Figure 2E). However, [3H]-bile acid secre-
tion into bile was not different between WT and NPC1L1-LiverTg
mice in the absence or presence of LXR agonist (Figure 2F),
which coincides with mass measurements (Temel et al., 2007;
data not shown). However, there was no difference in [3H]-
cholesterol recovery in the liver between WT and NPC1L1-LiverTg
mice on either treatment (Figure 2G). In stark contrast to the
biliary [3H]-cholesterol recovery (Figure 2E), fecal [3H]-choles-
terol recovery in WT and NPC1L1-LiverTg was identical following
treatment with vehicle or the LXR agonist (Figure 2H). As previ-
ously reported (Naik et al., 2006), LXR activation did increase
fecal [3H]-cholesterol recovery, but it did so to the same extent
in mice with normal enterohepatic circulation (WT) and thoseCell Metabolism 12, 96–102, July 7, 2010 ª2010 Elsevier Inc. 97
Figure 2. Macrophage RCT Is Normal in
Mice Genetically Engineered to Lack the
Ability to Secrete Cholesterol into Bile
Wild-type mice (- in bar graphs) or NPC1L1-
LiverTg (, in bar graphs, L1-Tg) littermates were
maintained on a standard chow diet in the
absence (Vehicle) or presence of the LXR agonist
T0901317 (25 mg/kg per day) for 7 days. During
the last 48 hr, mice were singly housed, and
macrophage to feces RCT was measured as
described in the Experimental Procedures.
(A) Total plasma cholesterol (TPC) levels.
(B) Mass cholesterol distribution of pooled plasma
(n = 4 per pool).
(C) Time course of [3H]-cholesterol recovery in
plasma; *, significantly different than WT vehicle
group within each time point, p < 0.05.
(D) [3H]-cholesterol distribution of pooled plasma
(n = 4 per pool).
(E) [3H]-cholesterol recovery in newly secreted
bile.
(F) [3H]-bile acid recovery in newly secreted bile.
(G) [3H]-cholesterol recovery in the liver.
(H) [3H]-cholesterol recovery in the feces.
(I) [3H]-bile acids recovery in the feces.
(J) [3H]-cholesterol recovery in the SI wall.
(K) Mass biliary cholesterol concentrations in
newly secreted bile.
(L) Mass fecal neutral sterol loss. Results are
combined from two independent experiments.
Data in (A), (C), (E), (F), (G), (H), (I), and (J) represent
the means ± SEM from seven to eleven mice per
group, and data in (K) and (L) represent means ±
SEM from five to nine mice per group. Means not
sharing a common superscript differ significantly,
p < 0.05.
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(NPC1L1-LiverTg) (Figure 2H). This effect seems to be specific to
neutral sterol loss, since fecal [3H]-bile acid recovery was not
significantly different between any of the groups (Figure 2I).
Interestingly, the [3H]-cholesterol tracer recovery in the small
intestinal (SI) wall (Figure 2J) was as high as levels seen in the
liver (3%–5% of the dose; Figure 2G). The recovery in the
SI wall was not significantly different between WT and
NPC1L1- LiverTg mice but wasmodestly increased by LXR activa-
tion (Figure 2J). When examining cholesterol mass, vehicle-
treated NPC1L1-LiverTg mice compared to WT mice had a 78%
reduction in cholesterol concentration in bile (Figure 2K), yet
fecal neutral sterol loss was similar between the two genotypes
(Figure 2L). LXR activation did result in significant increases in
biliary cholesterol in both genotypes (Figure 2K), but the levels
seen in NPC1L1-LiverTg mice only reached that of vehicle-treated
WT mice (Figure 2K). In contrast, fecal neutral sterol loss in
T091317-treated WT and NPC1L1-LiverTg mice was significantly
higher than that of vehicle-treated counterparts (Figure 2L),
further supporting the disconnect between biliary sterol secre-
tion and fecal neutral sterol loss in these mice.
Surgical Biliary Diversion Reveals the Existence
of a Nonbiliary Pathway for Macrophage RCT
AlthoughNPC1L1-LiverTgmice serve as an excellentmodel where
nonbiliary sterol loss predominates, there is a small residual98 Cell Metabolism 12, 96–102, July 7, 2010 ª2010 Elsevier Inc.amount of biliary sterol loss in this genetic model (Figures 1A
and 2K). In order to more definitively test whether bile is required
for macrophage RCT, we set out to create a surgical model
where there would be no biliary emptying into the small intestine,
without obstructing bile flow. To do this, we surgically diverted
bile flow away from the small intestine (Figure 3A). Once this
biliary diversion, or an appropriate sham surgery, was complete,
mice were allowed to recover from anesthesia and received
a [3H]-cholesterol-labeled macrophage foam cell dose via an
externalized port in order to avoid accidental injection directly
into the intestine. Quite strikingly, the appearance of [3H]-choles-
terol in the intestinal lumen was no different between sham-
operated and surgically diverted mice (Figure 3B). Furthermore,
LXR activation resulted in significant increases in the lumenal
appearance of [3H]-cholesterol in both sham and diverted
animals (Figure 3B), further supporting the notion that LXR acti-
vation promotes primarily the nonbiliary pathway for fecal sterol
loss (Kruit et al., 2005; van der Veen et al., 2009). Importantly, the
lumenal appearance of [3H]-bile acids was completely blocked
by surgical biliary diversion (Figure 3C), which agrees with
previous mass data in dogs (Sperry, 1927; Pertsemlidis et al.,
1973). These data support the notion that bile is the only route
for hepatic bile acids to reach the SI lumen, while cholesterol
delivery into the intestine and feces can persist in the absence
of biliary return (Sperry, 1927; Pertsemlidis et al., 1973; Dietschy,
1968; Figure 3). Interestingly, at this early 8 hr time point after
Figure 3. Surgical Biliary Diversion Reveals
the Existence of a Nonbiliary Pathway for
Macrophage RCT
Wild-type C57BL/6N mice were maintained on a
standard chow diet in the absence (Vehicle) or
presence of the LXR agonist T0901317 (25 mg/kg
per day) for 7 days.
(A) The experimental design is as follows: following
7 days of vehicle or LXR agonist treatment, mice
were either shamoperated or underwent complete
surgical bile diversion as described in the Experi-
mental Procedures. Thereafter, mice received a
[3H]-cholesterol-labeled macrophage (MF) dose
via an externalized peritoneal port in order to
ensure no dose was accidentally injected into the
intestine. After 8 hr, the SI lumenal contents and
wall were collected and extracted to separate
[3H]-cholesterol and [3H]-bile acids.
(B) [3H]-cholesterol recovered in the SI lumenal
contents.
(C) [3H]-bile acids recovered in the SI lumenal
contents.
(D) [3H]-cholesterol recovered in the SI wall. Data
represent the means ± SEM from five to nine
mice per group, andmeans not sharing a common
superscript differ significantly, p < 0.05.
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dose can be found in the SI wall (Figure 3D). There was no differ-
ence in the SI wall recovery between sham and diverted animals,
yet LXR activation did significantly increase [3H]-cholesterol
recovery in the SI wall under conditions of intact and diverted
enterohepatic circulation (Figure 3D). Collectively, these data
support the notion that macrophage RCT can persist in the
complete absence of biliary contributions.
DISCUSSION
Although it is generally accepted that macrophage RCT depends
entirely on the ability of the liver to secrete HDL-delivered choles-
terol into bile (Lewis and Rader, 2005), results from this study
suggest that the current conceptual framework of macrophage
RCT requires significant modification. The major findings of the
current study are the following: (1) mice genetically lacking the
ability to adequately secrete cholesterol into bile (NPC1L1-LiverTg
mice) have normal LXR-inducible macrophage RCT, and (2) mice
surgically lacking biliary contributions to the intestine have
normal LXR-inducible macrophage RCT. Importantly, the
genetic and surgical models defined in this work should continue
to serve as useful tools to further interrogate the molecular
mechanisms mediating nonbiliary fecal sterol loss and macro-
phage RCT.
The relative contribution of biliary versus nonbiliary pathways
to fecal sterol loss has not been fully defined. Using an intestinal
perfusion system, it was estimated that44%of total fecal sterol
output originated from nonbiliary sources in humans (Simmonds
et al., 1967). In normal chow-fed C57BL/6J mice, the nonbiliary
route accounts for 33% (76 mmol/kg/day) of total fecal neutral
sterol loss (van der Veen et al., 2009) and roughly 20% of total
fecal sterol loss in FVB mice (Kruit et al., 2005). However, it is
important to point out that nonbiliary fecal sterol loss is quite
sensitive to pharmacological manipulation. To this end, LXRactivation can dramatically augment nonbiliary macrophage
RCT (Figures 2 and 3) and increase mass fecal neutral sterol
loss (Kruit et al., 2005; van der Veen et al., 2009). In fact, LXR
activation in C57BL/6J increases the contribution of nonbiliary
fecal sterol loss from 33% of the total (76 mmol/kg/day) in
vehicle-treated mice to 63% of the total (442 mmol/kg/day) in
T0901317-treated mice (van der Veen et al., 2009). Furthermore,
activation of the peroxisome proliferator-activated receptor
d (PPAR-d) promotes nonbiliary fecal sterol loss in mice (Vrins
et al., 2009). Importantly, now in three independent genetically
modified mouse models (ABCG5/G8/, Mdr2/, and
NPC1L1-LiverTg) that have severely diminished biliary cholesterol
secretion, fecal sterol loss is only modestly decreased (Yu et al.,
2002) or not altered at all (Kruit et al., 2005; Figure 1). This clearly
indicates that the nonbiliary pathway must be able to adequately
compensate for biliary insufficiency to maintain normal fecal
sterol loss in rodents. Collectively, these data support the idea
that fecal sterol loss is a mixture of dietary, biliary, and intesti-
nally derived sterols, and the origins of the latter source likely
originate from the plasma compartment (Brown et al., 2008;
Kruit et al., 2005; van der Veen et al., 2009). Given the plasma
source of intestinally derived fecal sterols, and the central role
of the liver in lipoprotein metabolism, one must consider the
liver as a potential site of organization for nonbiliary fecal sterol
loss.
The classic view of RCT involves the delivery of peripheral
cholesterol via HDL to the liver for secretion into bile (Lewis
and Rader, 2005; deGoma et al., 2008). In parallel, we believe
that the liver also plays a gatekeeper role for nonbiliary fecal
sterol loss by repackaging peripheral cholesterol into nascent
plasma lipoproteins that are destined for subsequent intestinal
delivery (Brown et al., 2008). Probably not coincidentally, all of
the mouse models described in which nonbiliary fecal sterol
loss is apparent (Figure 1; Brown et al., 2008; Kruit et al., 2005;
Temel et al., 2007) represent conditions where free cholesterolCell Metabolism 12, 96–102, July 7, 2010 ª2010 Elsevier Inc. 99
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elimination pathways. It remains possible that under conditions
where hepatic free cholesterol burden becomes too excessive
for disposal through esterification or biliary secretion (i.e.,
ACAT2 ASO treatment [Brown et al., 2008], NPC1L1-Liver-Tg
mice [Figure 1; Temel et al., 2007], or Mdr2/ mice [Kruit
et al., 2005]), an alternative plasma-based route for direct intes-
tinal secretion and fecal disposal is utilized. In previous work, we
were able to show that the liver can secrete lipoprotein particles
that preferentially deliver cholesterol to the proximal small intes-
tine for fecal excretion (Brown et al., 2008). However, whether
these liver-derived lipoproteins represent nascent VLDL parti-
cles, nascent HDL particles, or some novel lipoprotein remains
to be addressed. Interestingly, unlike the genetic models of
biliary cholesterol insufficiency (ABCG5/G8/, Mdr2/, and
NPC1L1-LiverTg), acute surgical diversion of bile is a situation in
which normal elimination pathways such as esterification or
biliary secretion are not obviously impaired, yet de novo choles-
terol synthesis is augmented (Figure S1; Dietschy, 1968; Deckel-
baum et al., 1977; Pertsemlidis et al., 1973; Bandsma et al.,
1998). In this case it has been assumed that the origin of fecal
sterols in bile-diverted animals comes from the enhanced de
novo synthesis (Dietschy, 1968; Deckelbaum et al., 1977;
Pertsemlidis et al., 1973; Bandsma et al., 1998). However, our
data suggest that a small portion of the fecal sterols present in
bile-diverted mice is derived from direct intestinal secretion of
macrophage-derived cholesterol. This is supported by the fact
that we have added an intact [3H]-cholesterol molecule delivered
via J774 macrophages, excluding any contribution from endog-
enous synthesis.
Although macrophage RCT is agreed to be key to the regres-
sion of atherosclerosis, it is important to discuss the quantitative
importance of macrophages in RCT and centripetal flux of
cholesterol into the feces. To put macrophage RCT in perspec-
tive to the total process of centripetal cholesterol flux, it has
been estimated that there are only 1 3 108 macrophages in
the adult mouse (Lee et al., 1985). Hence, the number of macro-
phages in the whole body represents only a small fraction of the
other cell types present, making the relative contribution of
macrophages to mass fecal neutral sterol loss extremely small.
Even though macrophages are a minor contributor to mass fecal
neutral sterol loss, macrophage-specific RCT is likely highly
relevant to atherosclerosis regression in the artery wall (Lewis
and Rader, 2005). Therefore, it is also important to discuss
whether themacrophage RCT assay used in this work truly reca-
pitulates the process thought to occur in the artery wall. Since
the original description (Zhang et al., 2003) of the assay used
in our studies, there have been over 30 independent studies
described in the literature utilizing this method. Collectively,
these studies indicate that once the [3H]-cholesterol-labeled
J774 macrophages are injected, these cells remain primarily
within the peritoneal cavity, and the appearance of [3H]-choles-
terol in the plasma and tissues is not likely due to the direct trans-
port of the tracer by intact J774 cells (Zhang et al., 2003; Naik
et al., 2006; Wang et al., 2007; Rader et al., 2009). Instead, the
bulk of evidence suggests that a small fraction of [3H]-cholesterol
tracer is removed from the J774 macrophages by traditional
efflux mechanisms, and once effluxed this tracer is metabolized
in a manner comparable to endogenous cholesterol mass100 Cell Metabolism 12, 96–102, July 7, 2010 ª2010 Elsevier Inc.(Zhang et al., 2003; Naik et al., 2006; Wang et al., 2007; Rader
et al., 2009). It is important to note that the seemingly modest
fecal recovery (1%–4%) of injected [3H]-cholesterol (Figure 2H)
may actually be substantial, given that only 1%–5% was found
in the plasma over the 48 hr period (Figure 2C). Whether this
assay truly recapitulates the process of macrophage RCT from
the artery wall is still a matter of debate, but there is good
evidence that determining the rate of macrophage RCT using
this assay accurately predicts atherosclerosis burden in mice
(Rader et al., 2009). However, given the assay limitations, and
the relatively small contributions of macrophages to fecal sterol
loss, it remains critically important for investigators to quantify
mass fecal sterol loss to more accurately determine whole-
body centripetal cholesterol flux in future studies.
It has been over 80 years since Warren Sperry speculated that
a nonbiliary route for fecal neutral sterol loss must exist in dogs
(Sperry, 1927). Unfortunately, this alternative pathway has
been largely ignored, and very little progress has been made to
identify the molecular mechanisms that define it. There is now
strong evidence in mice (Figures 1–3; Kruit et al., 2005; van der
Velde et al., 2007, 2008; van der Veen et al., 2009; Vrins et al.,
2009; Brown et al., 2008; Plosch et al., 2002), and mounting
evidence in man (Simmonds et al., 1967; Cheng and Stanley,
1959; Deckelbaum et al., 1977), that a nonbiliary pathway for
fecal sterol loss indeed exists. In order to more fully understand
this pathway, the following challenges will need to be addressed:
(1) establishing quantitative methods to measure nonbiliary fecal
sterol loss in primates and man, (2) identifying the intestinal
transport proteins/receptors involved, (3) characterizing the lipo-
protein metabolism that is requisite for nonbiliary fecal sterol
loss, and (4) identifying bona fide drug targets to specifically
modulate the intestinal component of RCT. Advancement in
these areas has the potential to open new therapeutic opportu-
nities targeting the intestine as an inducible sterol excretory
organ.EXPERIMENTAL PROCEDURES
In Vivo Macrophage RCT Studies in NPC1L1-LiverTg Mice
In vivo measurement of macrophage RCT was conducted essentially as
described by Rader and colleagues (Zhang et al., 2003; Naik et al., 2006),
with minor modifications. Extensive descriptions of the mouse models used,
cell culture protocols, and RCT method are included in the Supplemental
Information.
In Vivo Macrophage RCT Studies with Acute Surgical Biliary
Diversion
C57BL/6N mice maintained on standard rodent chow were gavaged with
either vehicle or 25 mg/kg T0901317 daily for 7 consecutive days prior to
surgical biliary diversion. The surgical procedure used to acutely divert biliary
emptying into the intestine and macrophage RCT protocol is included in the
Supplemental Information.
Plasma Lipoprotein Distribution Analysis
Detailed description of plasma lipid analyses is included in the Supplemental
Information.
Quantitative Real-Time PCR
RNA extraction and quantitative real-time PCR (qPCR) were conducted as
previously described (Brown et al., 2008) using the DD-CT method. Primers
used for qPCR are available upon request.
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Data are expressed as the mean ± standard error of the mean (SEM). All data
were analyzed using two-way analysis of variance (ANOVA) followed by
Student’s t tests for post hoc analysis. Differences were considered significant
at p < 0.05. All analyses were performed using JMP version 5.0.12 (SAS
Institute; Cary, NC) software.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and one figure and can be found with this article online at doi:10.1016/
j.cmet.2010.05.011.ACKNOWLEDGMENTS
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